H.C. Wainwright analyst Andrew Fein raised the firm’s price target on United Therapeutics (UTHR) to $525 from $500 and keeps a Buy rating on the shares following the Q3 report. The firm cites Tyvaso revenue growth and the “strong” early launch of Yutrepia for the target boost.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on UTHR:
- United Therapeutics price target raised to $447 from $435 at Morgan Stanley
- United Therapeutics: Hold Rating Amid Optimistic Partnership Prospects and Adjusted Revenue Goals
- United Therapeutics Reports Record Q3 2025 Results
- United Therapeutics Corp’s Earnings Call Highlights Growth and Innovation
- Strong Growth Potential and Strategic Initiatives Drive Buy Rating for United Therapeutics